glp 1 and blood pressure meds Do GLP-1 Medications Affect Other Drugs? GLP-1 Hypertension: A New Edge

Bivalirudin is often used during certain cardiac procedures

Something went wrong while submitting the form.

Recent GLP-1 Weight Loss Drug Market Developments: Novo Nordisk, Eli Lilly, Amgen, and FDA Lead 20252026 April 2026: Eli Lilly submitted the orforglipron New Drug Application to the FDA for obesity treatment, reporting 14.7% body weight reduction in the ATTAIN-WEIGHT1 Phase 3 trial at the 45mg dose the first oral small molecule GLP-1 receptor agonist NDA submission for dedicated obesity pharmacological treatment in the United States

In addition to clinical guidance, the statement also includes a closer look at evidence gaps and opportunities for further research, including a closer look at what intentional weight loss strategy offers the greatest HF benefit, the role of cardiometabolic health clinics in HF care, and whether AOMs may improve outcomes in individuals with HF with reduced ejection fraction (HFrEF)